Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Zhengzhou
Clinical trial register · China

Clinical Trials in Zhengzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Henan Cancer Hospital75 The First Affiliated Hospital of Zhengzhou University38 Merck Sharp & Dohme LLC28 AbbVie21 Novartis Pharmaceuticals20
Site location
Beijing5576 Shanghai3879 Guangzhou3345 Hangzhou1819 Wuhan1343
All 625 locations
Target enrolment
to

Trials with a site in Zhengzhou

931 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
The First Affiliated Hospital of Zhengzhou University
Observational
300
Zhengzhou
2024-09-01
Recruiting
Jiayuan Sun
Not applicable
110
Guangzhou, Zhengzhou, Shanghai, Chengdu, Hangzhou
2024-09-01
Recruiting
Mingzhi Zhang
Phase 1/2
50
Zhengzhou
2024-09-01
Active, closed
Servier Bio-Innovation LLC
Phase 1/2
48
Beijing, Harbin, Zhengzhou, Shenyang, Jinan, Shanghai, Hangzhou
2024-08-31
Active, closed
AstraZeneca
Phase 2
194
Beijing, Hangzhou, Jinan, Yantai, Zhengzhou
2024-08-27
Active, closed
AbbVie
Phase 3
699
Beijing, Yuzhong District, Xiamen, Shenzhen, Zhengzhou, Changsha, Dalian, Chengdu
2024-08-19
Recruiting
Yi Zhang
Early Phase 1
100
Zhengzhou
2024-08-18
Recruiting
Shubo Song
Not applicable
10
Zhengzhou
2024-08-16
Recruiting
The First Affiliated Hospital of Zhengzhou University
Phase 2
208
Zhengzhou
2024-08-15
Active, closed
Genmab
Phase 3
379
Beijing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2024-08-13
Recruiting
DK Medical Technology (Suzhou) Co., Ltd.
Not applicable
140
Beijing, Guangzhou, Shenzhen, Zhengzhou, Nanjing, Shanghai
2024-08-13
Recruiting
A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
NCT06615193Advanced Solid Tumors, Refractory Lymphoma, Relapsed Hematologic Malignancy
DrugHDM2005
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
111
Zhengzhou, Suzhou, Xuzhou, Nanchang, Jinan, Hangzhou, Tianjing
2024-08-12
Active, closed
AbbVie
Phase 3
111
Beijing, Guangzhou, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai, Hangzhou
2024-08-08
Recruiting
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
NCT06445972Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
DrugsPatritumab deruxtecan·Ramucirumab·Sacituzumab tirumotecan·Paclitaxel
Merck Sharp & Dohme LLC
Phase 1/2
210
Beijing, Fuzhou, Xiamen, Zhengzhou, Nanchang, Shanghai, Ürümqi, Hangzhou
2024-08-07
Active, closed
Iptacopan in Patients With ANCA Associated Vasculitis
NCT06388941Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
DrugsIptacopan·Rituximab
Novartis Pharmaceuticals
Phase 2
84
Shijiazhuang, Zhengzhou, Beijing
2024-08-05
Recruiting
Akeso
Phase 3
469
Zhengzhou, Changsha, Nanjing, Hangzhou
2024-08-02
Not yet open
Henan Cancer Hospital
Phase 1
30
Zhengzhou
2024-08-01
Not yet open
Henan Cancer Hospital
Phase 2
46
Zhengzhou
2024-08
Recruiting
Zhengzhou Children's Hospital, China
Not applicable
90
Chengdu, Liangshan, Zhengzhou, Ziyang
2024-07-31
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Not applicable
320
Beijing, Guangzhou, Shenzhen, Zhengzhou, Nanjing, Dalian, Jinan, Xi’an
2024-07-31
Recruiting
JIANGSU SHENMING Medical Technology CO., Ltd
Not applicable
216
Hefei, Beijing, Nanning, Guiyang, Shijiazhuang, Anyang, Luoyang, Zhengzhou
2024-07-29
Recruiting
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
144
Beijing, Guangzhou, Zhengzhou, Shenyang, Jinan, Shanghai
2024-07-24
Active, closed
MAXVAX Biotechnology Limited Liability Company
Phase 3
25,000
Shijiazhuang, Zhengzhou, Wuhan, Kunming
2024-07-13
Active, closed
Efficacy and Safety of Colchicine After PCI
NCT06472908Coronary Heart Disease, Percutaneous Coronary Intervention, Colchicine
DrugColchicine
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 3
8,862
Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Harbin, Zhengzhou, Enshi
2024-07-09
Recruiting
A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations
NCT06500676KRAS G12D Mutations, Advanced Solid Tumors
DrugCetuximab
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2
407
Hefei, Beijing, Guangzhou, Nanning, Haerbin, Zhengzhou, Wuhan, Changsha
2024-07-09
Active, closed
Novartis Pharmaceuticals
Phase 4
318
Hefei, Fuzhou, Guangzhou, Shenzhen, Zunyi, Harbin, Zhengzhou, Wuhan
2024-07-09
Recruiting
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 or 2 Systemic Treatment Regimens
NCT06127407Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
DrugIvosidenib
Servier Bio-Innovation LLC
Phase 3
156
Guangzhou, Zhengzhou, Wuhan, Changsha, Shang'ai, Shanghai, Chengdu, Hangzhou
2024-07-09
Not yet open
The First Affiliated Hospital of Zhengzhou University
Phase 2
20
Zhengzhou
2024-07-06
Active, closed
Novartis Pharmaceuticals
Phase 4
36
Guangzhou, Zhengzhou, Wuhan, Xian, Hangzhou, Beijing, Taian, Tianjin
2024-07-04
Recruiting
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1/2
156
Zhengzhou, Hangzhou
2024-07-02
Recruiting
DRug-coAted Balloon Compared With cuttinG balloON in Treatment of Arteriovenous Fistula Stenosis
NCT06527963Arteriovenous Fistula, Angioplasty, Balloon, Hemodialysis Access Failure
RenJi Hospital
Observational
180
Zhengzhou, Nanjing, Shanghai
2024-07-01
Not yet open
The First Affiliated Hospital with Nanjing Medical University
Not applicable
66
Hefei, Zhengzhou, Nanjing, Beijing
2024-07-01
Not yet open
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
54
Beijing, Zhengzhou, Changsha, Changchun, Jinan, Shanghai, Taiyuan, Tianjin
2024-07
Recruiting
Boehringer Ingelheim
Phase 1/2
910
Changchun, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Zhengzhou
2024-06-28
Recruiting
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
316
Beijing, Fuzhou, Guangzhou, Nanning, Zhengzhou, Changsha, Nanjing, Shanghai
2024-06-25
Recruiting
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 3
264
Anhui Sheng, Beijing, Guangzhou, Zunyi, Shijiazhuang, Zhengzhou, Changsha, Wuhan
2024-06-25
Recruiting
Avistone Biotechnology Co., Ltd.
Phase 1
63
Beijing, Harbin, Zhengzhou, Jinan, Shanghai
2024-06-24
Active, closed
Lyvgen Biopharma Holdings Limited
Phase 2
64
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Zhengzhou, Wuhan, Changsha
2024-06-21
Recruiting
The Impact of Lifestyle Intervention on Weight and Fertility in Obese Males
NCT06339840Obesity, Weight Loss, Male Fertility, Artificial Insemination
Third Affiliated Hospital of Zhengzhou University
Not applicable
98
Zhengzhou
2024-06-20
Recruiting
Henan Cancer Hospital
Phase 2
48
Zhengzhou
2024-06-19
Recruiting
Guangzhou Virotech Pharmaceutical Co., Ltd.
Phase 1
30
Guangzhou, Zhengzhou, Jinan
2024-06-19
Active, closed
Celgene
Phase 3
850
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin, Zhengzhou
2024-06-19
Recruiting
Henan Provincial People's Hospital
Not applicable
48
Zhengzhou
2024-06-15
Recruiting
Hangzhou Sumgen Biotech Co., Ltd.
Phase 3
360
Beijing, Guangzhou, Luoyang, Zhengzhou, Wuhan, Suzhou, Taiyuan, Xi’an
2024-06-14
Recruiting
A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
NCT06574568Relapsed or Refractory Multiple Myeloma
DrugYKST02
Excyte Biopharma Ltd
Phase 1
70
Beijing, Foshan, Guangzhou, Nanning, Harbin, Zhengzhou, Dalian, Jinan
2024-06-14
Recruiting
Merck Sharp & Dohme LLC
Phase 3
851
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Wuhan
2024-06-10
Active, closed
Min Yan, MD
Phase 2
40
Zhengzhou
2024-06-06
Recruiting
Mobile Applet for Weight Management in Obese Heart Failure Patients
NCT06455878Heart Failure, Overweight and Obesity, Weight Loss, Heart Failure With Reduced Ejection Fraction
Heart Health Research Center
Not applicable
830
Beijing, Guangzhou, Langfang, Jixi, Luoyang, Shangqiu, Xinyang, Zhengzhou
2024-06-06
Recruiting
Juventas Cell Therapy Ltd.
Observational
200
Beijing, Guangzhou, Zhengzhou, Wuhan, Xuzhou, Jinan, Shanghai, Chengdu
2024-06-05
Recruiting
A Trail of Sperstent® Used for Residual Lesions of Femoropopliteal Arteries
NCT06539689Peripheral Arterial Disease, Stenosis, Dissection
FrontAce Scientific Co., Ltd
Not applicable
240
Beijing, Chongqing, Shijiazhuang, Zhengzhou, Wuhan, Nanjing, Nantong, Shanghai
2024-06-04
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
252
Fuzhou, Guangzhou, Nanning, Haikou, Shijiazhuang, Harbin, Anyang, Zhengzhou
2024-06-04
Recruiting
RenJi Hospital
Observational
180
Zhengzhou, Nanjing, Shanghai
2024-06-01
Not yet open
Henan Cancer Hospital
Phase 2
30
Zhengzhou
2024-06
Active, closed
Amgen
Phase 1
120
Fuzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Changchun
2024-05-29
Recruiting
Linperlisib Combined With Chidamide in Patients With PTCL
NCT06421948Peripheral T-cell Lymphoma
Yanyan Liu
Phase 1/2
134
Zhengzhou, Wuhan, Changsha, Chengdu, Tianjin, Hangzhou
2024-05-25
Recruiting
A Study of GLB-001 in Patients With Myeloid Malignancies
NCT06378437Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis, Myelodysplastic Syndromes
DrugGLB-001
Hangzhou GluBio Pharmaceutical Co., Ltd.
Phase 1
108
Hefei, Beijing, Chongqing, Shijiazhuang, Zhengzhou, Wuhan, Suzhou, Nanchang
2024-05-24
Recruiting
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
130
Beijing, Fuzhou, Guangzhou, Zhengzhou, Nanjing, Tianjin, Hanzhou
2024-05-24
Recruiting
A Study of GQ1010 in Subjects With Advanced Solid Tumors
NCT06464055Advanced Malignant Solid Tumors
DrugPhase II
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Phase 1/2
260
Beijing, Harbin, Tianjin, Wuhan, Zhengzhou
2024-05-23
Recruiting
IDEAL Study: Blinded RCT for the Impact of AI Model for Cerebral Aneurysms Detection on Patients' Diagnosis and Outcomes
NCT06118840Intracranial Aneurysm, CT Angiography, Deep Learning, Double Bind Interaction
Jinling Hospital, China
Not applicable
6,450
Hefei, Wuhu, Guiyang, Zhengzhou, Shiyan, Nanjing, Xuzhou, Changchun
2024-05-20
Active, closed
AbbVie
Phase 3
421
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Nanjing, Suzhou, Nanchang
2024-05-19
Active, closed
Bristol-Myers Squibb
Phase 4
84
Beijing, Guangzhou, Shenzhen, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Nanchang
2024-05-15
Recruiting
Henan University of Traditional Chinese Medicine
Not applicable
120
Zhengzhou
2024-05-11
Active, closed
Zhengzhou University
Observational
37
Zhengzhou
2024-05-01
Not yet open
Henan University of Traditional Chinese Medicine
Observational
1,508
Zhengzhou
2024-05-01
Not yet open
Henan University of Traditional Chinese Medicine
Observational
3,600
Zhengzhou
2024-05-01
Recruiting
DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)
NCT06539182Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
DrugBirelentinib
Dizal Pharmaceuticals
Phase 2
155
Hefei, Beijing, Guangzhou, Zhengzhou, Wuhan, Nanjing, Changchun, Dalian
2024-04-29
Recruiting
Peking Union Medical College Hospital
Observational
3,000
Hefei, Beijing, Nanning, Zhengzhou, Henan, Ningbo, Shanghai, Wuhan
2024-04-19
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
138
Bengbu, Beijing, Chengde, Harbin, Zhengzhou, Wuhan, Zhuzhou, Shenyang
2024-04-17
Recruiting
Harbin Medical University
Not applicable
1,860
Beijin, Zunyi, Daqing, Harbin, Jiamusi, Mudanjiang, Zhengzhou, Wuhan
2024-04-16
Recruiting
Henan University of Traditional Chinese Medicine
Observational
5,000
Zhengzhou
2024-04-15
Recruiting
Ascentage Pharma Group Inc.
Phase 3
344
Bengbu, Guangzhou, Zhanjiang, Zhengzhou, Wuhan, Changsha, Shanghai, Tianjin
2024-04-07
Recruiting
Eye & ENT Hospital of Fudan University
Observational
180
Beijing, Zhengzhou, Changsha, Nanchang, Shanghai, Chengdu
2024-04-06
Recruiting
Merck Sharp & Dohme LLC
Phase 3
780
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Suzhou
2024-04-03
By invitation
Henan Cancer Hospital
Phase 2
41
Zhengzhou
2024-04-02
Recruiting
Grit Biotechnology
Phase 2
83
Beijing, Fuzhou, Shenzhen, Guilin, Ha’erbin, Luoyang, Zhengzhou, Wuhan
2024-04-02
Recruiting
Henan Cancer Hospital
Phase 2
63
Zhengzhou
2024-04-01
Not yet open
Sinocelltech Ltd.
Phase 1
76
Beijing, Zhengzhou, Tianjin
2024-04
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
400
Beijing, Chongqing, Fuzhou, Anyang, Zhengzhou, Huai'an, Nanjing, Jinan
2024-03-30
Recruiting
Second Affiliated Hospital of Nanchang University
Phase 4
424
Hefei, Heihe, Fuzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha
2024-03-28
Recruiting
Shenyang Sunshine Pharmaceutical Co., LTD.
Phase 1/2
132
Zhengzhou
2024-03-27
Active, closed
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 2
240
Langfang, Xingtai, Zhengzhou, Jingzhou, Wuhan, Jinan, Liaocheng, Changzhi
2024-03-24
Recruiting
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 2
180
Beijing, Chongqing, Zhengzhou, Nanjing, Shenzhen
2024-03-22
Active, closed
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
NCT06380660Solid Tumor, Adult, BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer
Acerand Therapeutics (Shanghai) Limited
Phase 1/2
298
Chongqing, Fuzhou, Guangzhou, Anyang, Zhengzhou, Wuhan, Changsha, Jinan
2024-03-22
Recruiting
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1
108
Zhengzhou, Wuhan, Nanchang, Tianjin, Hangzhou
2024-03-21
Recruiting
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2
51
Nanning, Zhengzhou
2024-03-20
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
80
Zhengzhou, Nanjing, Suzhou, Shanghai, Wenzhou
2024-03-19
Recruiting
Anhui Provincial Hospital
Phase 3
198
Hefei, Beijing, Zhengzhou, Wuhan, Shanghai, Hangzhou
2024-03-15
Recruiting
A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCT06313957Relapsed B-cell Non-Hodgkin Lymphoma, Refractory B-cell Non-Hodgkin Lymphoma
Peking University Cancer Hospital & Institute
Phase 1
42
Beijing, Zhengzhou
2024-03-14
Recruiting
Sino Medical Sciences Technology Inc.
Not applicable
300
Zhengzhou
2024-03-08
Recruiting
Suzhou Genhouse Bio Co., Ltd.
Phase 1/2
94
Hefei, Zhengzhou, Changsha, Nanjing, Shanghai, Linhai
2024-03-05
Recruiting
Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation
NCT06316960AML, Childhood, Relapse/Recurrence, Refractory AML, Core Binding Factor Acute Myeloid Leukemia
DrugsIdarubicin Hydrochloride·Granulocyte Colony-Stimulating Factor·Avapritinib·Decitabine
Children's Hospital of Soochow University
Phase 2
50
Hefei, Guangzhou, Nanning, Kaifeng, Zhengzhou, Changsha, Suzhou, Xuzhou
2024-03-01
Recruiting
Henan Cancer Hospital
Phase 1
30
Zhengzhou
2024-03-01
Recruiting
The First Affiliated Hospital of Zhengzhou University
Not applicable
20
Zhengzhou
2024-03-01
Active, closed
Anhui Provincial Hospital
Phase 3
198
Hefei, Beijing, Zhengzhou, Wuhan, Shanghai, Hangzhou
2024-03-01
Active, closed
Novartis Pharmaceuticals
Phase 3
1,466
Beijing, Guangzhou, Harbin, Zhengzhou, Nanjing, Nanchang, Changchun, Jinan
2024-02-28
Recruiting
Henan Cancer Hospital
Phase 1/2
70
Zhengzhou
2024-02-28
Recruiting
Henan Cancer Hospital
Phase 2
224
Zhengzhou
2024-02-23
Recruiting
Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer
NCT07334431Gastric Adenocarcinoma, Gastric (Stomach) Cancer, GEJ Adenocarcinoma, HER2-positive Gastric Cancer
DrugXelox
Henan Cancer Hospital
Phase 1/2
45
Zhengzhou
2024-02-22
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 2
100
Hefei, Beijing, Hunan, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan
2024-02-22
Active, closed
Abbisko Therapeutics Co, Ltd
Phase 1
164
Hefei, Fuzhou, Xi'an, Harbin, Zhengzhou, Wuhan, Changsha, Nanchang
2024-02-22
Recruiting
RemeGen Co., Ltd.
Phase 2/3
90
Beijing, Xiamen, Harbin, Zhengzhou, Wuhan, Changsha, Xuzhou, Jinan
2024-02-22
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
762
Hefei, Fuzhou, Foshan, Guangzhou, Jiangmen, Nanning, Luoyang, Zhengzhou
2024-02-21
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 3
404
Beijing, Chongqing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Yangzhou
2024-02-20
Not yet open
Henan Cancer Hospital
Phase 2
48
Zhengzhou, Wuhan
2024-02-10
Active, closed
Genmab
Phase 3
1,095
Beijing, Xiamen, Guangzhou, Shenzhen, Nanning, Zhengzhou, Wuhan, Changsha
2024-02-05
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
150
Chongqing, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing, Dalian, Shenyang
2024-02-01
Recruiting
Myasthenia Gravis Registry in China
NCT06241521Myasthenia Gravis
Huashan Hospital
Observational
1,500
Beijing, Chongqing, Guangzhou, Zhengzhou, Changsha, Suzhou, Xuzhou, Nanchang
2024-02-01
Recruiting
Huabo Biopharm Co., Ltd.
Phase 1/2
282
Baoding, Harbin, Luoyang, Zhengzhou, Lianyungang, Shenyang, Jinan, Linyi
2024-01-31
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
121
Chongqing, Fuzhou, Guangzhou, Liuzhou, Luoyang, Zhengzhou, Wuhan, Changsha
2024-01-29
Recruiting
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1/2
42
Beijing, Bengbu, Changchun, Chengdu, Fuzhou, Zhengzhou, Zhongshan
2024-01-26
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 1
339
Hefei, Beijing, Xiamen, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha
2024-01-23
Recruiting
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
152
Beijing, Guangzhou, Haerbin, Zhengzhou, Wuhan, Changsha, Jinan, Qingdao
2024-01-23
Active, closed
Janssen Research & Development, LLC
Phase 3
112
Beijing, Changzhou, Hangzhou, Shanghai, Shenyang, Zhengzhou
2024-01-19
Recruiting
Zhongnan Hospital
Phase 3
154
Zhengzhou, Huanggang, Jingzhou, Shiyan, Wuhan, Xianning, Xiaogan, Yichang
2024-01-18
Recruiting
Henan Cancer Hospital
Not applicable
22
Zhengzhou
2024-01-15
Recruiting
Risen (Suzhou) Pharma Tech Co., Ltd.
Phase 1/2
306
Zhengzhou
2024-01-11
Recruiting
Hangzhou GluBio Pharmaceutical Co., Ltd.
Phase 1
110
Beijing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanchang, Shenyang
2024-01-11
Recruiting
Multi-omics Study for Early Detection of Colorectal Cancer (MOED-CRC)
NCT06220617Colorectal Cancer, Adenomatous Polyps, Adenoma, Advanced Adenoma
Zhejiang University
Observational
3,600
Hangzhou, Guangzhou, Kunming, Nanjing, Xi'an, Zhengzhou
2024-01-11
Recruiting
Chengdu New Radiomedicine Technology Co. LTD.
Phase 1
58
Zhengzhou, Suzhou, Shanghai, Chongqing, Tianjin
2024-01-09
Recruiting
Respiratory Disease Cohort Studies of Chinese Medicine for Pulmonary Nodule
NCT06673121Pulmonary Nodule, Cohort Study, Traditional Chinese Medicine
Third Affiliated Hospital of Henan University of Traditional Chinese Medicine
Observational
5,000
Zhengzhou
2024-01-03
Recruiting
Henan Cancer Hospital
Phase 2
240
Zhengzhou
2024-01-01
Recruiting
Shanghai Chest Hospital
Not applicable
100
Zhengzhou, Beijing, Chengdu, Linyi, Nanchang, Shanghai, Shijiazhuang, Zhejiang
2024-01-01
Recruiting
Jianning Yao
Not applicable
60
Zhengzhou
2024-01-01
Recruiting
Children's Hospital of Soochow University
Phase 2
500
Hefei, Guangzhou, Nanning, Kaifeng, Zhengzhou, Changsha, Suzhou, Xuzhou
2024-01-01
Recruiting
Central South University
Observational
2,000
Hefei, Zhengzhou, Changsha, Nanjing
2024-01-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
340
Bengbu, Hefei, Beijing, Quanzhou, Xiamen, Guangzhou, Shijiazhuang, Zhengzhou
2023-12-31
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
DrugSurovatamig
AstraZeneca
Phase 1/2
255
Changsha, Chengdu, Guangzhou, Hangzhou, Nanjing, Suzhou, Tianjin, Zhengzhou
2023-12-29
Recruiting
Bristol-Myers Squibb
Phase 1/2
460
Beijing, Guangzhou, Zhengzhou, Suzhou, Nanchang, Shenyang, Qingdao, Shanghai
2023-12-29
Recruiting
Teligene US
Phase 2
66
Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing, Nanchang, Jinan
2023-12-27
Recruiting
Hinova Pharmaceuticals Inc.
Phase 1/2
84
Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Guiyang, Zhengzhou
2023-12-26
Recruiting
Henan Provincial People's Hospital
Observational
400
Zhengzhou
2023-12-26
Recruiting
Bivision Pharmaceuticals, Inc.
Phase 1/2
90
Hefei, Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Suzhou, Wuxi
2023-12-22
Active, closed
Bristol-Myers Squibb
Phase 3
190
Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-12-21
Recruiting
Ascentage Pharma Group Inc.
Phase 3
400
Hefei, Beijing, Fuzhou, Foshan, Guangzhou, Nanning, Zhengzhou, Wuhan
2023-12-20
Recruiting
Tavotek Biotherapeutics
Phase 1
50
Chongqing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Jinan
2023-12-20
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3
324
Bengbu, Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanchang, Dalian
2023-12-19
Recruiting
Shandong First Medical University
Phase 4
1,200
Chongqing, Zhengzhou, Binzhou, Dezhou, Feicheng, Jinan, Liaocheng, Linqing
2023-12-18
Recruiting
Hansoh BioMedical R&D Company
Phase 2
170
Hefei, Beijing, Fuzhou, Guangzhou, Zhuhai, Nanning, Harbin, Zhengzhou
2023-12-18
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
92
Guangzhou, Nanning, Cangzhou, Chengde, Tangshan, Xingtai, Harbin, Zhengzhou
2023-12-12
Recruiting
AbbVie
Phase 3
110
Beijing, Guangzhou, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai
2023-12-11
Recruiting
Jinzhou Medical University
Not applicable
80
Zhengzhou
2023-12-03
Recruiting
Beijing Hospital
Phase 2
296
Hefei, Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Hohhot, Shenyang
2023-12-02
Not yet open
Gang Wu
Not applicable
70
Zhengzhou
2023-12-01
Recruiting
RemeGen Co., Ltd.
Phase 2
90
Beijing, Fuzhou, Kunming, Xiamen, Wuwei, Guangzhou, Harbin, Zhengzhou
2023-11-27
Recruiting
Henan Cancer Hospital
Phase 1
20
Zhengzhou
2023-11-21
Active, closed
TransThera Sciences (Nanjing), Inc.
Phase 2
50
Hefei, Beijing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Harbin, Zhengzhou
2023-11-17
Active, closed
Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL
NCT06093841Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma, Mediastinal B-Cell Diffuse Large Cell Lymphoma
DrugsRelmacabtagene Autoleucel·Relma-cel·Fludarabine·Cyclophosphamide
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 2
46
Guangzhou, Zhengzhou, Changsha, Suzhou, Jinan, Shanghai, Tianjin, Hangzhou
2023-11-03
Recruiting
IN10018 Combination Therapy in Treatment-naïve ES-SCLC
NCT06030258Small Cell Lung Cancer Extensive Stage
DrugsIN10018·Etoposide·Tislelizumab·Carboplatin
InxMed (Shanghai) Co., Ltd.
Phase 1/2
120
Jinan, Tianjin, Zhengzhou
2023-10-30
Recruiting
Allist Pharmaceuticals, Inc.
Phase 2
88
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-10-27
Recruiting
Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
NCT05978284Small Cell Lung Cancer, Neuroendocrine Carcinoma
DrugZG006
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2
54
Zhengzhou
2023-10-27
Active, closed
Bristol-Myers Squibb
Phase 3
1,057
Hefei, Beijing, Lanzhou, Guangzhou, Shenzhen, Shenzhen Shi, Zhengzhou, Shijiazhuang
2023-10-25
Active, closed
Bristol-Myers Squibb
Phase 3
402
Hefei, Beijing, Chongqing, Xiamen, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2023-10-24
Active, closed
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
NCT05952037Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory
DrugsSonrotoclax·Zanubrutinib
BeOne Medicines
Phase 2
114
Xiamen, Guangzhou, Zhengzhou, Wuhan, Yancheng, Shenyang, Qingdao, Shanghai
2023-10-23
Active, closed
Zhengzhou University
Phase 4
34
Zhengzhou
2023-10-21
Recruiting
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
180
Beijing, Fuzhou, Zhengzhou, Changsha, Nanjing, Nanchang, Changchun, Jinan
2023-10-19
Recruiting
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1/2
63
Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Yongzhou, Shenzhen, Xi’an
2023-10-17
Recruiting
BioSyngen Pte Ltd
Early Phase 1
14
Zhengzhou
2023-10-09
Not yet open
Henan Provincial People's Hospital
Phase 2
30
Zhengzhou
2023-10-05
Not yet open
Fudan University
Phase 4
384
Shijiazhuang, Zhengzhou, Changsha, Nantong, Yangzhou, Shanghai, Hangzhou, Jiaxin
2023-10
Recruiting
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 2
56
Beijing, Chongqing, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Chengdu, Hangzhou
2023-09-28
Recruiting
Recurrent High Grade Glioma Treated by LITT
NCT06161610Recurrent High Grade Glioma
Beijing Tiantan Hospital
Not applicable
135
Beijing, Guangzhou, Zhengzhou, Wuhan, Changchun, Shenyang, Jinan, Shanghai
2023-09-19
Active, closed
Bristol-Myers Squibb
Phase 3
1,255
Hefei, Beijing, Guangzhou, Shenzhen, Shenzhen Shi, Zhengzhou, Shijiazhuang, Yichang Shi
2023-09-14
By invitation
argenx
Phase 3
240
Guangzhou, Nanjing, Beijing, Chengdu, Shanghai, Shenyang, Zhengzhou
2023-09-12
Recruiting
A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
NCT06064812Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer Stage IV, ER+/HER2- Breast Cancer
DrugFWD1802
Forward Pharmaceuticals Co., Ltd.
Phase 1/2
99
Hefei, Guangzhou, Huizhou, Nanning, Luoyang, Xinxiang, Zhengzhou, Wuhan
2023-09-12
Recruiting
Henan Cancer Hospital
Phase 2
69
Zhengzhou
2023-09-12
Active, closed
Bristol-Myers Squibb
Phase 3
774
Beijing, Xiamen, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Changsha, Hohhot
2023-09-11
Recruiting
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
NCT06051409Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
DrugOlverembatinib
Ascentage Pharma Group Inc.
Phase 3
350
Bengbu, Chongqing, Guangdong, Zhengzhou, Wuhan, Suzhou, Shanghai, Chengdu
2023-08-31
Recruiting
Haihe Biopharma Co., Ltd.
Phase 1/2
141
Beijing, Fuzhou, Guangzhou, Zhengzhou, Changsha, Shanghai, Chengdu
2023-08-22
Recruiting
DualityBio Inc.
Phase 1/2
1,000
Zhengzhou, Changsha, Nanjing, Wuxi, Changchun, Shenyang, Shanghai, Chengdu
2023-08-17
Active, closed
Sinocelltech Ltd.
Phase 3
18,000
Nanning, Zhengzhou, Taiyuan, Chengdu, Kunming
2023-08-13
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
364
Hefei, Beijing, Chongqing, Nanning, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2023-08-11
Active, closed
CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)
NCT05896124Primary Biliary Cholangitis (PBC)
DrugPleacbo
Cascade Pharmaceuticals, Inc
Phase 2
75
Hefei, Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Zhenjiang, Changchun
2023-08-07
Recruiting
Tong Chen, MD
Phase 1/2
30
Hefei, Beijing, Fuzhou, Zhengzhou, Shanghai
2023-08-03
Recruiting
a Single-arm, Single-center, Open Clinical Study
NCT06431100Gastric Cancer, Esophageal Cancer, Cervical Cancer, Non-Small Cell Lung Cancer NSCLC
Beijing Geekgene Technology Co., LTD
Observational
10
Zhengzhou
2023-07-19
Recruiting
The Maintenance Treatment of "ITIVA" in AML Patients
NCT06256627Acute Myeloid Leukemia, Maintenance Treatment, Minor Residue Disease, Interferon-α-1b
Henan Cancer Hospital
Not applicable
130
Zhengzhou
2023-07-11
Recruiting
CARsgen Therapeutics Co., Ltd.
Phase 1
20
Beijing, Zhengzhou, Wuhan, Changsha, Shanghai, Xian, Hangzhou
2023-07-11
Recruiting
Henan Cancer Hospital
Phase 2
66
Zhengzhou
2023-07-05
Active, closed
Abbisko Therapeutics Co, Ltd
Phase 1
169
Chongqing, Luoyang, Zhengzhou, Wuhan, Changsha, Hohhot, Nanchang, Changchun
2023-06-26
Active, closed
Bristol-Myers Squibb
Phase 3
1,230
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Zhengzhou, Changsha, Nanjing
2023-06-22
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 4
360
Hefei, Beijing, Lanzhou, Nanning, Shijiazhuang, Tianjin, Zhengzhou, Wuhan
2023-06-19
Recruiting
Hansoh BioMedical R&D Company
Phase 2
170
Beijing, Changsha, Guangzhou, Hangzhou, Nanjing, Shanghai, Tianjin, Zhengzhou
2023-06-08
Active, closed
Yongxu Jia
Phase 2
37
Zhengzhou
2023-06-07
Active, closed
Eli Lilly and Company
Phase 3
3,127
Hefei, Beijing, Chongqing, Shenzhen, Haikou, Harbin, Luoyang Shi, Zhengzhou
2023-06-05
Recruiting
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT05797168Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma
DrugsPalacaparib·Torvutatug samrotecan·Saruparib·Paraplatin
AstraZeneca
Phase 1/2
622
Chengdu, Chongqing, Guangzhou, Jinan, Xi'an, Zhengzhou
2023-06-05
Active, closed
GeneCradle Inc
Phase 1/2
16
Beijing, Changsha, Hangzhou, Zhengzhou
2023-06-02
Active, closed
ArriVent BioPharma, Inc.
Phase 3
398
Beijing, Meizhou, Xuhui, Hangzhou, Cangzhou, Shushan, Zhengzhou, Changchun
2023-06-01
Recruiting
SG1906 for CLDN18.2-Positive Solid Tumors
NCT05857332Locally Advanced Unresectable or Metastatic Solid Tumors
Hangzhou Sumgen Biotech Co., Ltd.
Phase 1
60
Beijing, Xiamen, Guangzhou, Zhengzhou, Shenyang, Taiyuan, Hangzhou
2023-05-30
Recruiting
Henan Cancer Hospital
Observational
200
Zhengzhou
2023-05-20
Active, closed
Biotheus Inc.
Phase 2
31
Chongqing, Fuzhou, Harbin, Zhengzhou, Jingzhou, Wuhan, Changsha, Yongzhou
2023-05-17
Recruiting
Takeda
Phase 3
240
Beijing, Zhengzhou, Changsha, Shanghai, Hangzhou
2023-05-16
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
230
Hefei, Beijing, Xiamen, Xinxiang, Zhengzhou, Huai'an, Shanghai, Hangzhou
2023-05-16
Active, closed
Shanghai Chest Hospital
Observational
305
Hefei, Xiamen, Guangzhou, Harbin, Zhengzhou, Changsha, Jinan, Shanghai
2023-05-08
Active, closed
AstraZeneca
Phase 3
37
Beijing, Chongqing, Yangzhou, Zhengzhou
2023-05-08
Recruiting
Henan Cancer Hospital
Phase 2
610
Zhengzhou
2023-05-03
Recruiting
Sun Yat-sen University
Phase 3
540
Guangzhou, Guiyang, Harbin, Zhengzhou, Wuhan, Nanchang, Dalian, Shanghai
2023-04-30
Recruiting
Lenvatinib for Advanced Bone and Soft Tissue Sarcoma
NCT05617859Effectiveness, Sexuality
DrugLenvatinib
Henan Cancer Hospital
Phase 2
60
Zhengzhou
2023-04-30
Active, closed
Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)
NCT05804045Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath
DrugPimicotinib
Abbisko Therapeutics Co, Ltd
Phase 3
94
Bengbu, Beijing, Fuzhou, Guangzhou, Guiyang, Zhengzhou, Enshi, Wuhan
2023-04-27
Recruiting
GONGCHU Biotechnology Co., Ltd
Phase 1
21
Zhengzhou
2023-04-26
Active, closed
Klus Pharma Inc.
Phase 2
356
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-04-19
Recruiting
ZHOU FANGJIAN
Phase 3
298
Beijing, Guangzhou, Hefei, Shanghai, Sichuan, Tianjin, Zhengzhou
2023-04-19
Recruiting
Qilu Hospital of Shandong University
Phase 4
2,600
Bozhou, Chuzhou, Hefei, Beijing, Zunyi, Zhengzhou, Dalian, Xining
2023-04-12
Recruiting
Henan Cancer Hospital
Observational
300
Zhengzhou
2023-04-04
Recruiting
Shanghai Hongdian Medical CO., LTD
Not applicable
180
Chongqing, Xiamen, Lanzhou, Guangzhou, Guiyang, Harbin, Zhengzhou, Zhenzhou
2023-03-31
Recruiting
Henan Cancer Hospital
Phase 2
150
Zhengzhou
2023-03-31
Recruiting
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
220
Beijing, Chongqing, Fuzhou, Nanning, Harbin, Luoyang, Zhengzhou, Changsha
2023-03-27
Active, closed
Merck Sharp & Dohme LLC
Phase 3
300
Beijing, Chongqing, Guangzhou, Guiyang, Haikou, Zhengzhou, Wuhan, Changsha
2023-03-16
Recruiting
Teligene US
Phase 2
60
Beijing, Chongqing, Fuzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha
2023-03-16
Active, closed
AbbVie
Phase 3
520
Bengbu, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-03-15
Active, closed
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
219
Fuzhou, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing, Shenyang, Xi'an
2023-03-09
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1
191
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Zhengzhou
2023-03-09
Recruiting
The First Affiliated Hospital of Zhengzhou University
Phase 2
112
Zhengzhou
2023-03-08
Recruiting
The First Affiliated Hospital of Zhengzhou University
Phase 2
188
Zhengzhou
2023-03-02
Recruiting
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 1
52
Zhengzhou, Shijiazhuang, Hangzhou, Beijing, Shanghai
2023-03-02
Recruiting
Sun Yat-sen University
Phase 3
176
Hefei, Foshan, Guangzhou, Nanning, Harbin, Zhengzhou, Nanchang, Shanghai
2023-03-01
Not yet open
Peking University First Hospital
Observational
2,000
Hefei, Beijing, Chongqing, Zhengzhou, Shanghai
2023-03
Recruiting
Xijing Hospital of Digestive Diseases
Phase 2/3
104
Beijing, Guangzhou, Zhengzhou, Changsha, Nanjing, Shenyang, Xi'an, Yan’an
2023-02-17
Recruiting
A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML
NCT05641259Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
DrugAzacitidine
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 1
198
Nanchang, Suzhou, Zhengzhou
2023-02-14
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
7
Beijing, Guangzhou, Zhengzhou
2023-02-10
Active, closed
Genmab
Phase 3
900
Beijing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2023-02-08
Active, closed
Novartis Pharmaceuticals
Phase 3
226
Beijing, Guangzhou, Shenzhen, Shijiazhuang, Luoyang, Zhengzhou, Changzhou, Nanchang
2023-02-03
Active, closed
BeiGene
Phase 1/2
113
Hefei, Beijing, Fuzhou, Quanzhou, Xiamen, Guangzhou, Shantou, Zhengzhou
2023-01-29
Active, closed
ABTECT - Maintenance
NCT05535946Ulcerative Colitis
DrugObefazimod
Abivax S.A.
Phase 3
1,116
Wuhu, Beijing, Fuzhou, Guangzhou, Luoyang, Zhengzhou, Wuhan, Shenyang
2023-01-16
Recruiting
AstraZeneca
Phase 2
163
Beijing, Hangzhou, Harbin, Hefei, Kunming, Wuhan, Yinchuan, Zhengzhou
2023-01-16
Active, closed
Bristol-Myers Squibb
Phase 3
516
Bengbu, Beijing, Xiamen, Guangzhou, Shenzhen, Baoding, Luoyang, Zhengzhou
2023-01-12
Active, closed
Bristol-Myers Squibb
Phase 3
606
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Nantong
2023-01-10
Active, closed
BeiGene
Phase 1/2
113
Beijing, Fuzhou, Lanzhou, Guangzhou, Nanning, Zhengzhou, Wuhan, Changsha
2023-01-09
Recruiting
Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
NCT05722275Gastric Cancer, Peritoneal Metastases
Chinese Academy of Sciences
Observational
400
Beijing, Fuzhou, Guangzhou, Guiyang, Kunming, Taiyuan, Zhengzhou, Zhenjiang
2023-01-01
Recruiting
Broadenbio Ltd., Co.
Phase 1
78
Guangzhou, Zhengzhou
2022-12-29
Recruiting
Henan Provincial People's Hospital
Phase 2
80
Zhengzhou
2022-12-23
Recruiting
Zhenzhen Liu
Phase 2
369
Zhengzhou
2022-12-20
Not yet open
Henan Provincial People's Hospital
Observational
60
Zhengzhou
2022-12-20
Active, closed
Prognostic Value of the AMR Measured After PPCI in STEMI Patients
NCT05653765Coronary Heart Disease, ST Elevation Myocardial Infarction
Henan Institute of Cardiovascular Epidemiology
Observational
2,663
Shangqiu, Xinxiang, Yongcheng, Zhengzhou, Shanghai
2022-12-20
Not yet open
Henan Provincial People's Hospital
Observational
100
Zhengzhou
2022-12-17
Not yet open
Henan Provincial People's Hospital
Phase 2
60
Zhengzhou
2022-12-11
Not yet open
Henan Provincial People's Hospital
Phase 2
70
Zhengzhou
2022-12-01
Not yet open
Henan Provincial People's Hospital
Observational
50
Zhengzhou
2022-12-01
Active, closed
Primary Cervical Cancer Screening by Self-sampling HPV Test
NCT05613283Human Papillomavirus Infection, Cervical Cancer, Negative For Intraepithelial Lesion Or Malignancy, Atypical Squamous Cells of Undetermined Significance
Peking University People's Hospital
Observational
17,875
Beijing, Zhengzhou, Changsha, Chengdu, Hangzhou
2022-11-19
Active, closed
Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis
NCT05486104Moderate to Severe Ulcerative Colitis
DrugMufemilast
Ganzhou Hemay Pharmaceutical Co., Ltd
Phase 2
92
Hefei, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanchang, Shenyang
2022-11-08
Recruiting
MSD R&D (China) Co., Ltd.
Phase 1/2
203
Chongqing, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Xuzhou, Chengdu
2022-11-01
Recruiting
Henan Genuine Biotech Co., Ltd.
Phase 1/2
153
Beijing, Guangzhou, Zhengzhou
2022-10-31
Recruiting
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
470
Hefei, Wuhu, Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha
2022-10-26
Active, closed
Genmab
Phase 3
549
Beijing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha
2022-09-20
Active, closed
Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
NCT05471843Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma
DrugSonrotoclax
BeOne Medicines
Phase 1/2
125
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Haikou, Zhengzhou, Wuhan
2022-09-05
Recruiting
Teligene US
Phase 2
128
Bengbu, Beijing, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha
2022-09-01
Active, closed
Sinotau Pharmaceutical Group
Phase 3
196
Beijing, Fuzhou, Xiamen, Guangzhou, Zhengzhou, Wuhan, Nanjing, Changchun
2022-08-31
Recruiting
Asciminib Roll-over Study
NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
DrugsAsciminib single agent·Bosutinib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 4
347
Chongqing, Guangzhou, Zhengzhou, Wuhan, Changchun, Xian, Chengdu, Beijing
2022-08-30
Recruiting
Fudan University
Not applicable
80
Nanning, Zhengzhou, Changsha, Shanghai, Kunming, Hangzhou
2022-08-25
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
153
Beijing, Chongqing, Nanning, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing
2022-08-23
Recruiting
Henan Cancer Hospital
Phase 2
79
Zhengzhou
2022-08-19
Recruiting
Allist Pharmaceuticals, Inc.
Phase 1/2
104
Beijing, Chongqing, Xiamen, Shenzhen, Nanning, Shijiazhuang, Harbin, Zhengzhou
2022-08-17
Recruiting
Zhengzhou University
Observational
100
Zhengzhou
2022-08-12
Active, closed
Novo Nordisk A/S
Phase 3
412
Beijing, Guangzhou, Liuzhou, Sanya, Zhengzhou, Wuhan, Changsha, Changchun
2022-08-10
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
348
Fuzhou, Dongguan, Guangdong, Zhengzhou, Wuhan, Jinan, Hangzhou
2022-08-09
Recruiting
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Phase 1
150
Zhengzhou, Changsha, Shanghai
2022-08-08
Recruiting
Study on Clinical Features, Treatment Mode and Survival of Bone and Soft Tissue Tumors
NCT05468970Bone and Soft Tissue Tumors, Clinical Features
Henan Cancer Hospital
Observational
6,000
Zhengzhou
2022-08-03
Recruiting
D3 Bio (Wuxi) Co., Ltd
Phase 1/2
442
Hefei, Beijing, Guangzhou, Hangzhou, Harbin, Wuhan, Changsha, Zhengzhou
2022-08-03
Recruiting
Henan Cancer Hospital
Phase 3
219
Zhengzhou
2022-08-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
251
Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Nanjing, Suzhou, Nanchang
2022-07-27
Recruiting
Henan Cancer Hospital
Phase 2
43
Zhengzhou
2022-07-26
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
DrugsNemtabrutinib·Zilovertamab vedotin
Merck Sharp & Dohme LLC
Phase 2
189
Beijing, Guangzhou, Zhengzhou, Wuhan, Suzhou, Xuzhou, Nanchang, Chuangchun
2022-07-21
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
206
Fuzhou, Xiamen, Lanzhou, Guangzhou, Yulin, Zhengzhou, Changsha, Nanchang
2022-07-20
Recruiting
Fudan University
Observational
385
Hefei, Shijiazhuang, Zhengzhou, Nantong, Taishing, Taizhou, Xi'an, Tianjin
2022-07-18
Active, closed
INSPIRIS China PMCF Study
NCT05404880Aortic Valve Replacement
Edwards Lifesciences
Observational
255
Beijing, Xiamen, Guangzhou, Shenzhen, Zhengzhou, Nanjing, Xi'an, Chengdu
2022-07-13
Active, closed
Pfizer
Phase 2
35
Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Changchun, Shenyang
2022-07-07
Active, closed
ArriVent BioPharma, Inc.
Phase 1
160
Hefei, Beijing, Chaoyang, Chongqing, Harbin, Zhengzhou, Wuhan, Xuzhou
2022-06-30
Active, closed
A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC
NCT05319431Unresectable, Non-metastatic Hepatocellular Carcinoma
DrugsCadonilimab·Lenvatinib
Akeso
Phase 2
60
Beijing, Guangzhou, Zhengzhou, Changsha, Jinan
2022-06-28
Recruiting
The First Affiliated Hospital of Zhengzhou University
Phase 2
60
Zhengzhou
2022-06-20
Active, closed
Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma
NCT05363800Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
74
Zhengzhou, Shengyang, Hangzhou
2022-06-17
Active, closed
Merck Sharp & Dohme LLC
Phase 1
12
Guangzhou, Zhengzhou, Changsha, Tianjin
2022-06-09
Recruiting
Astellas Pharma Global Development, Inc.
Phase 1
398
Guangzhou, Zhengzhou, Wuhan, Shanghai, Hangzhou
2022-06-07
Recruiting
NOACs Use in AF or VTE (SUNSHINE Registry)
NCT05378308Atrial Fibrillation, Venous Thromboembolism, Oral Anticoagulant
Henan Provincial People's Hospital
Observational
5,000
Zhengzhou
2022-06-06
Active, closed
Intracranial Arterial Stenosis in Young Patients
NCT05844176Intracranial Arterial Stenosis
Capital Medical University
Observational
500
Suzhou, Shijiazhuang, Beijing, Zhengzhou
2022-06-01
Recruiting
Zhuhai Yufan Biotechnologies Co., Ltd
Phase 1/2
267
Zhengzhou, Chengdu, Hangzhou, Beijing
2022-05-30
Recruiting
Beijing Tiantan Hospital
Observational
200
Beijing, Zhengzhou, Nanjing
2022-05-25
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
312
Guangzhou, Zhengzhou
2022-05-25
Active, closed
Henan Cancer Hospital
Phase 2
120
Zhengzhou
2022-05-20
Active, closed
A Study of AL8326 in Non-Small Cell Lung Cancer
NCT06794957Non-small Cell Lung Cancer
DrugAL8326
Advenchen Laboratories, LLC
Phase 1
158
Bengbu, Hefei, Xuancheng, Anyang, Zhengzhou, Wuhan, Nanjing, Hangzhou
2022-05-19
Active, closed
Henan Cancer Hospital
Phase 2
42
Zhengzhou
2022-05-13
Recruiting
Shanghai Zhongshan Hospital
Observational
6,000
Xiamen, Guangzhou, Zhengzhou, Wuhan, Jiangyin, Wuxi, Yangzhou, Yixing
2022-05-01
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
120
Hefei, Beijing, Zhengzhou, Jinan, Tianjin
2022-04-26
Active, closed
Hoffmann-La Roche
Phase 3
208
Chengdu, Fuzhou, Guangzhou, Tianjin, Wuhan, Zhengzhou
2022-04-25
Recruiting
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
NCT05288205KRAS P.G12C, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma
DrugsJAB-3312·Glecirasib
Allist Pharmaceuticals, Inc.
Phase 1/2
240
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Harbin, Zhengzhou
2022-04-14
Active, closed
Merck Sharp & Dohme LLC
Phase 3
460
Hefei, Beijing, Fuzhou, Harbin, Zhengzhou, Wuhan, Changsha, Suzhou
2022-03-24
Recruiting
Henan Cancer Hospital
Phase 2
134
Zhengzhou
2022-03-22
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,800
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Zhengzhou, Wuhan
2022-03-15
Active, closed
Sanofi
Phase 3
122
Beijing, Shanghai, Taiyuan, Zhengzhou
2022-03-11
Active, closed
Genmab
Phase 1/2
49
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Suzhou, Xuzhou
2022-03-10
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
654
Hefei, Guangzhou, Meizhou, Liuzhou, Nanning, Haikou, Baoding, Zhengzhou
2022-03-07
Recruiting
3D Medicines (Sichuan) Co., Ltd.
Phase 2
108
Beijing, Chongqing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Yueyang
2022-03-04
Active, closed
Daiichi Sankyo
Phase 3
740
Nanning, Zhengzhou, Changchun, Chengdu, Beijing, Cangzhou, Changsha, Chongqing
2022-03-04
Active, closed
Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC
NCT05092412Lung Cancer, Extensive-stage Small-cell Lung Cancer, Durvalumab
DrugDurvalumab
You Lu
Phase 2
30
Chongqing, Zhengzhou, Chengdu
2022-03-02
Recruiting
Zhejiang University
Phase 1
72
Hangzhou, Zhengzhou
2022-02-21
Active, closed
JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation
NCT05194995Advanced Colorectal Cancer, Small Intestinal Cancer, Appendiceal Cancer
DrugsGlecirasib·Cetuximab
Allist Pharmaceuticals, Inc.
Phase 1/2
48
Beijing, Nanning, Harbin, Zhengzhou, Wuhan, Changsha, Nanjing, Nanchang
2022-02-17
Recruiting
Takeda
Phase 3
120
Beijing, Zhengzhou, Shanghai, Hangzhou
2022-02-10
Active, closed
Shenzhen Core Medical Technology CO.,LTD.
Not applicable
50
Beijing, Fuzhou, Guangzhou, Wuhan, Changsha, Zhengzhou, Nanjing, Suzhou
2022-01-26
Active, closed
China S3 PMS: SAPIEN 3 China Post Market Registry Study
NCT05168826Aortic Stenosis, Severe
Edwards Lifesciences
Observational
250
Beijing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Changsha, Shanghai, Xi’an
2022-01-24
Recruiting
SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors
NCT05245058HER2-positive Advanced Solid Tumors
DrugSPH5030
Shanghai Pharmaceuticals Holding Co., Ltd
Early Phase 1
150
Hefei, Beijing, Guangzhou, Nanning, Shijiazhuang, Harbin, Anyang, Zhengzhou
2022-01-21
Recruiting
The First Affiliated Hospital of Zhengzhou University
Phase 2
130
Zhengzhou
2022-01-15
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
290
Beijing, Chongqing, Guangzhou, Luoyang, Zhengzhou, Wuhan, Nanchang, Changchun
2022-01-14
Active, closed
AbbVie
Phase 4
44
Beijing, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Xiangyang, Suzhou, Nanchang
2022-01-06
Recruiting
Clinical Trial of BAO-G Technique in Complex Aortic Aneurysm Endovascular Repair (BAO-G-02)
NCT07141251Thoracoabdominal Aortic Aneurysm, Endovascular Repair, Complex Aortic Aneurysms
Peking Union Medical College Hospital
Not applicable
60
Beijing, Chongqing, Guangzhou, Haikou, Zhengzhou, Jining, Shanghai
2022-01-01
Active, closed
Shanghai Xinzhi BioMed Co., Ltd.
Phase 2/3
32
Hefei, Beijing, Guangzhou, Shenzhen, Tangshan, Zhengzhou, Taiyuan, Tianjin
2021-12-30
Recruiting
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
NCT05147467Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugLisaftoclax
Ascentage Pharma Group Inc.
Phase 2
75
Guangzhou, Haikou, Zhengzhou, Wuhan, Suzhou, Nanchang, Tianjin, Hanzhou
2021-12-28
Recruiting
Henan Cancer Hospital
Phase 2
30
Zhengzhou
2021-12-21
Active, closed
Novartis Pharmaceuticals
Phase 3
1,000
Guangzhou, Zhengzhou, Changsha, Baotou, Hohhot, Nanchang, Changchun, Beijing
2021-12-16
Recruiting
Juventas Cell Therapy Ltd.
Early Phase 1
24
Zhengzhou
2021-12-14
Recruiting
Corheart 6: Long-term Cohort Study
NCT07094919Heart Failure
China National Center for Cardiovascular Diseases
Not applicable
160
Shenzhen, Zhengzhou, Wuhan, Nanjing, Beijing, Shanghai
2021-12-12
Active, closed
argenx
Phase 3
173
Beijing, Bengbu, Huizhou, Shenzhen, Tianjin, Wuhan, Wuxi, Zhengzhou
2021-11-17
Active, closed
Novartis Pharmaceuticals
Phase 3
153
Fuzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Xuzhou, Changchun, Chengdu
2021-11-15
Recruiting
Guangzhou Excelmab Inc.
Phase 1/2
415
Zhengzhou, Jinan, Shanghai, Tianjin
2021-11-12
Active, closed
SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
NCT04684108Relapsed or Refractory Multiple Myeloma, Hematological Malignancy
DrugSG301
Hangzhou Sumgen Biotech Co., Ltd.
Phase 1
61
Bengbu, Beijing, Shenzhen, Shijiazhuang, Zhengzhou, Wuhan, Xiangyang, Wuxi
2021-11-04
Active, closed
Takeda
Observational
72
Hefei, Beijing, Zhengzhou, Hohhot, Suzhou, Nanchang, Shenyang, Qingdao
2021-10-29
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
DrugsBosutinib·Asciminib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 3
405
Guangzhou, Shenzhen, Zhengzhou, Wuhan, Nanjing, Suzhou, Xian, Chengdu
2021-10-06
Recruiting
Pfizer
Phase 3
893
Beijing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Zhengzhou, Wuhan, Nanjing
2021-10-04
Recruiting
Henan Cancer Hospital
Phase 3
1,979
Zhengzhou
2021-09-28
Recruiting
Novartis Pharmaceuticals
Phase 3
540
Beijing, Guangzhou, Luoyang, Zhengzhou, Changsha, Changchun, Yinchuan, Taiyuan
2021-09-20
Recruiting
BeOne Medicines
Phase 1/2
246
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan
2021-09-16
Recruiting
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
NCT05006716B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
DrugTacabrutideg
BeOne Medicines
Phase 1/2
689
Beijing, Guangzhou, Zhengzhou, Yichang, Shanghai, Tianjin, Wenzhou
2021-09-13
Active, closed
AstraZeneca
Phase 3
98
Beijing, Ganzhou, Guangzhou, Jinan, Shenyang, Tianjin, Zhengzhou
2021-09-12
Recruiting
Zenith Epigenetics
Phase 2
200
Hefei, Chongqing, Xiamen, Zhengzhou, Wuhan, Changsha, Nanjing, Shenyang
2021-09-08
Active, closed
Nuvation Bio Inc.
Phase 2
217
Beijing, Zhengzhou, Shanghai, Changsha, Chengdu, Jinan, Wuhan
2021-09-01
Active, closed
Hoffmann-La Roche
Phase 3
4,170
Zhengzhou, Changsha, Nanchang, Changchun, Shanghai, Chengdu, Hangzhou, Beijing
2021-08-27
Active, closed
Bristol-Myers Squibb
Phase 3
729
Bengbu, Beijing, Guangzhou, Shenzhen, Zhengzhou, Changsha, Changzhou, Nanjing
2021-07-15
Recruiting
Henan Institute of Cardiovascular Epidemiology
Not applicable
400
Zhengzhou
2021-07-03
Recruiting
Quanli Gao
Observational
3,000
Zhengzhou
2021-07-01
Recruiting
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
NCT04900818Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer
DrugGivastomig
I-Mab Biopharma US Limited
Phase 1
330
Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Shenyang, Shanghai
2021-06-29
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
45
Hefei, Guangzhou, Nanning, Shijiazhuang, Zhengzhou, Wuhan, Suzhou, Tianjin
2021-06-25
Recruiting
Toripalimab Plus FLOT in Locally Advanced Gastric Cancer
NCT04891016Chemotherapy, Immune Checkpoint Inhibitor, Locally Advanced Gastric Carcinoma
DrugsFLOT·Toripalimab
Henan Cancer Hospital
Phase 2
60
Zhengzhou
2021-06-25
Active, closed
Mirati Therapeutics Inc.
Phase 3
461
Bengbu, Hefei, Beijing, Fuzhou, Guangzhou, Shenzhen, Nanning, Zhengzhou
2021-06-24
Active, closed
Merck Sharp & Dohme LLC
Phase 3
342
Hefei, Beijing, Xiamen, Foshan, Guangzhou, Shenzhen, Nanning, Zhengzhou
2021-06-18
Recruiting
Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
NCT04790305Carcinoma Breast, Triple-negative Breast Cancer, Invasive Ductal Carcinoma, Breast
DrugHuaier
Fudan University
Phase 4
1,072
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Harbin, Zhengzhou
2021-06-18
Recruiting
A Study of BGB-11417 in Participants With Myeloid Malignancies
NCT04771130Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm
DrugsPosaconazole·Sonrotoclax·Azacitidine
BeOne Medicines
Phase 1/2
260
Beijing, Lanzhou, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Suzhou, Nanchang
2021-05-24
Active, closed
Daiichi Sankyo
Phase 3
490
Heifi, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Changshan
2021-05-21
Active, closed
Pfizer
Phase 3
599
Hefei, Beijing, Lanzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing
2021-05-12
Active, closed
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
663
Bengbu, Hefei, Jiangmen, Shenzhen, Shijiazhuang, Anyang, Xinxiang, Zhengzhou
2021-05-12
Recruiting
Sellas Life Sciences Group
Phase 1/2
160
Bengbu, Hefei, Chongqing, Guangzhou, Baoding, Zhengzhou, Suzhou, Nanchang
2021-05-10
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,688
Bengbu, Beijing, Chongging, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou
2021-04-14
Recruiting
HANGZHOU Solution in Bicuspid AS Undergoing TAVR
NCT04722796Aortic Stenosis, Aortic Stenosis With Bicuspid Valve
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
508
Bengbu, Beijing, Fuzhou, Xiamen, Guangzhou, Zhengzhou, Wuhan, Changsha
2021-04-12
Active, closed
Loxo Oncology, Inc.
Phase 3
500
Hefei, Beijing, Fuzhou, Guangzhou, Luoyang, Zhengzhou, Wuhan, Yichang
2021-04-08
Recruiting
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
NCT04728893Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
DrugNemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
490
Hefei, Beijing, Chongqing, Guangzhou, Liuzhou, Nanning, Zhengzhou, Wuhan
2021-04-05
Recruiting
MSD R&D (China) Co., Ltd.
Phase 1
100
Beijing, Xiameng, Guangzhou, Shijiazhuang, Zhengzhou, Nanchang, Changchun, Jinan
2021-03-16
Recruiting
Henan Institute of Cardiovascular Epidemiology
Not applicable
210
Zhengzhou
2021-03-10
Recruiting
AstraZeneca
Phase 1
304
Changchun, Chengdu, Fuzhou, Shandong, Shanghai, Zhengzhou
2021-03-09
Active, closed
Loxo Oncology, Inc.
Phase 3
238
Beijing, Xicheng District, Lanzhou, Guangzhou, Haikou, Zhengzhou, Changsha, Xuzhou
2021-03-09
Active, closed
Chinese SLE Treatment And Research Group
Phase 3
146
Beijing, Shenzhen, Zhengzhou, Nanchang, Shenyang, Kunming
2021-03-04
Active, closed
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
NCT04279847Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myeloproliferative Neoplasm
DrugRuxolitinib
Incyte Corporation
Phase 1
140
Beijing, Guangzhou, Hangzhou, Zhengzhou
2021-02-23
Active, closed
Hoffmann-La Roche
Phase 3
270
Beijing, Guangzhou, Harbin, Shanghai, Tianjin, Wuhan, Zhejiang, Zhengzhou
2021-02-23
Active, closed
Novartis Pharmaceuticals
Phase 2
69
Hefei, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Changsha, Nanjing
2021-01-20
Recruiting
Henan Cancer Hospital
Phase 2
30
Zhengzhou
2021-01-13
Active, closed
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 2
59
Beijing, Fuzhou, Guanzhou, Zhengzhou, Nanjing, Shanghai, Tianjin, Hangzhou
2021-01-13
Active, closed
Amgen
Phase 1/2
181
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Suzhou, Qingdao, Xi’an
2021-01-04
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
30
Zhengzhou
2021-01-01
Active, closed
Prehabilitation Before Liver Surgery in Older Adults
NCT07877311Preoperative Prehabilitation in Older Adults Undergoing Hepatectomy
Lining Xu
Not applicable
500
Beijing, Shenzhen, Zhengzhou, Wuhan
2021-01-01
Active, closed
Novartis Pharmaceuticals
Observational
78
Fuzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Kunming, Hangzhou, Beijing
2020-12-31
Recruiting
Juventas Cell Therapy Ltd.
Phase 2
100
Beijing, Chongqing, Guangzhou, Sanhe, Zhengzhou, Wuhan, Xuzhou, Shanghai
2020-12-24
Active, closed
Merck Sharp & Dohme LLC
Phase 3
672
Beijing, Chongqing, Fuzhou, Xiamen, Shenzhen, Zhengzhou, Wuhan, Changsha
2020-12-08
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
60
Beijing, Chongqing, Xiamen, Zhengzhou, Wuhan, Shanghai, Chengdu
2020-11-10
Recruiting
Juventas Cell Therapy Ltd.
Phase 2
60
Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Jinan, Shanghai, Chengdu
2020-10-26
Active, closed
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
NCT04581473Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma
DrugsCT041 autologous CAR T-cell·Apatinib·Irinotecan
CARsgen Therapeutics Co., Ltd.
Phase 1/2
192
Hefei, Beijing, Fuzhou, Shenzhen, Harbin, Zhengzhou, Wuhan, Nanjing
2020-10-23
Recruiting
BurdEn of NEw Onset Atrial FIbrillation in patienTs With Acute Myocardial Infarction
NCT04528511Atrial Fibrillation New Onset, Acute Myocardial Infarction
Shanghai 10th People's Hospital
Observational
774
Kaifeng, Luoyang, Zhengzhou, Shanghai
2020-10-01
Active, closed
AbbVie
Phase 3
527
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Changsha
2020-09-30
Recruiting
Ascentage Pharma Group Inc.
Phase 1/2
682
Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Changsha, Suzhou, Shanghai
2020-09-28
Recruiting
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
NCT04557449Liposarcoma, Prostate Cancer, Advanced Breast Cancer, NSCLC (Non-small Cell Lung Cancer)
DrugAtirmociclib
Pfizer
Phase 1/2
430
Beijing, Zhengzhou, Wuhan, Xi’an, Hangzhou
2020-09-23
Active, closed
ADC Therapeutics S.A.
Phase 3
440
Beijing, Xiamen, Guangzhou, Zhengzhou, Changchun, Dalian, Shanghai, Chengdu
2020-09-16
Active, closed
AbbVie
Phase 3
531
Beijing, Lanzhou, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Nanjing, Suzhou
2020-09-10
Active, closed
A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.
NCT05395533CD20-positive B-cell Non-Hodgkin Lymphoma
DrugTRS005
Zhejiang Teruisi Pharmaceutical Inc.
Phase 1
147
Beijing, Guangzhou, Zhengzhou, Suzhou, Tianjin
2020-09-08
Recruiting
Evaluate the Safety and Clinical Activity of HH2853
NCT04390737FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor
DrugHH2853
Haihe Biopharma Co., Ltd.
Phase 1/2
254
Hefei, Beijing, Guangzhou, Nanning, Zhengzhou, Wuhan, Changsha, Nanjing
2020-09-08
Recruiting
MR Microstructural Imaging for Prostate Cancer Diagnosis
NCT07249281Prostate Cancer, Diffusion MRI
First Affiliated Hospital of Zhejiang University
Observational
2,000
Beijing, Zhengzhou, Nanjing, Dalian, Hangzhou
2020-09-01
Active, closed
Sun Yat-sen University
Not applicable
1,124
Chongqing, Lanzhou, Guangzhou, Shenzhen, Guilin, Zhengzhou, Wuhan, Nanjing
2020-08-25
Recruiting
InxMed (Shanghai) Co., Ltd.
Phase 1/2
150
Anyang, Beijing, Changsha, Fuzhou, Hangzhou, Tianjin, Zhengzhou
2020-07-27
Active, closed
AstraZeneca
Phase 3
134
Chengdu, Shanghai, Tianjin, Xiamen, Zhengzhou
2020-07-20
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
537
Beijing, Guangzhou, Zhengzhou, Nanjing, Shanghai, Chengdu, Hangzhou
2020-07-14
Active, closed
Merck Sharp & Dohme LLC
Phase 3
870
Beijing, Chongqing, Fuzhou, Xiamen, Shenzhen, Zhengzhou, Wuhan, Changsha
2020-07-06
Active, closed
Epizyme, Inc.
Phase 3
599
Fuzhou, Xiamen, Guiyang, Zhejiang, Shijiazhuang, Zhengzhou, Changsha, Changchun
2020-06-11
Active, closed
AstraZeneca
Phase 2
452
Chengdu, Guangzhou, Hefei, Shanghai, Shenyang, Wuhan, Zhengzhou
2020-06-03
Recruiting
Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma
NCT04280822Esophageal Cancer, Surgery, Neoadjuvant Treatment, Survival
Henan Cancer Hospital
Phase 3
400
Zhengzhou
2020-04-21
Active, closed
Loxo Oncology, Inc.
Phase 3
291
Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Harbin, Zhengzhou
2020-02-11
Active, closed
Henan Cancer Hospital
Phase 2
25
Zhengzhou
2020-01-20
Recruiting
Abbisko Therapeutics Co, Ltd
Phase 1
276
Beijing, Guangdong, Shijiazhuang, Zhengzhou, Nanjing, Shenyang, Shanghai, Xian
2020-01-20
Active, closed
BeOne Medicines
Phase 3
955
Beijing, Fuzhou, Quanzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing
2020-01-16
Recruiting
Fudan University
Phase 4
800
Fuzhou, Zhengzhou, Wuhan, Hohhot, Shanghai, Shanxi, Hangzhou, Beijing
2020-01-01
Active, closed
Regeneron Pharmaceuticals
Phase 2
515
Beijing, Tianjin, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan, Suzhou
2019-11-13
Active, closed
Geneplus-Beijing Co. Ltd.
Observational
757
Beijing, Shenzhen, Zhengzhou, Changsha, Nanjing, Changchun, Jinzhou, Chengdu
2019-11-12
Recruiting
Henan Cancer Hospital
Phase 3
456
Zhengzhou
2019-10-22
Recruiting
Non-invasive Urinary Genomics-Based Risk Assessment for Early Urothelial Carcinoma Diagnosis
NCT07614594Urothelial Carcinoma (UC), Upper Tract Urothelial Carcinoma, UTUC, Bladder Cancer (BC)
Henan Provincial People's Hospital
Observational
800
Zhengzhou
2019-10-08
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
466
Guangzhou, Zhanjiang, Zhengzhou, Changsha, Wuhan, Nanjing, Xuzhou, Nanchang
2019-10-02
Active, closed
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
NCT06239155Advanced Solid Tumors, Hepatocellular Carcinoma
DrugAST-3424
Ascentawits Pharmaceuticals, Ltd
Phase 1/2
51
Guangzhou, Zhengzhou, Nanjing, Shenyang, Shanghai, Hangzhou
2019-09-03
Active, closed
Henan Cancer Hospital
Phase 2
60
Anyang, Luoyang, Zhengzhou
2019-08-26
Active, closed
BeOne Medicines
Phase 3
510
Beijing, Fuzhou, Quanzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha
2019-08-20
Active, closed
Quantitative Flow Ratio (QFR) Guided Coronary Artery Bypass Grafting for Patients Undergoing Primary Valve Surgery With Concomitant Coronary Artery Disease
NCT03977129Primary Valvular Heart Disease With Comorbid Coronary Artery Disease, Planned to Undergo Elective On-pump Valve Surgery Due to Primary Mitral and/or Aortic Valvular Heart Disease
Ruijin Hospital
Not applicable
792
Hefei, Fuzhou, Zhengzhou, Changsha, Jinan, Qingdao, Shanghai, Tianjin
2019-08-04
Recruiting
Haihe Biopharma Co., Ltd.
Phase 1/2
183
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Haikou, Harbin, Zhengzhou
2019-07-15
Active, closed
Decreasing Risk of Psychosis by Sulforaphane (DROPS Trial)
NCT03932136Clinical High Risk Syndrome of Psychosis
Shanghai Jiao Tong University School of Medicine
Phase 3
300
Guangzhou, Zhengzhou, Changsha, Suzhou, Shanghai, Shenzhen, Tianjin
2019-07-14
Active, closed
Ascentage Pharma Group Inc.
Phase 1
80
Guangzhou, Zhengzhou, Changchun
2019-07-04
Active, closed
Ascentage Pharma Group Inc.
Phase 1
74
Hefei, Zhengzhou, Wuhan, Tianjin, Hangzhou
2019-06-03
Recruiting
APG-2449 in Patients With Advanced Solid Tumors
NCT03917043Advanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer, Ovarian Cancer
DrugAPG -2449
Ascentage Pharma Group Inc.
Phase 1
165
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Hangzhou
2019-05-27
Active, closed
Celgene
Phase 1/2
438
Beijing, Guangzhou, Zhengzhou, Wuhan, Shenyang, Shanghai, Tianjin
2019-05-20
Active, closed
Eisai Inc.
Phase 3
1,906
Beijing, Guangzhou, Shijiazhuang, Zhengzhou, Changsha, Baotou, Nanjing, Changchun
2019-03-27
Recruiting
Shantou University Medical College
Observational
940
Fuzhou, Guangzhou, Sanya, Shantou, Zhengzhou
2019-01-10
Recruiting
Henan Cancer Hospital
Observational
200
Zhengzhou
2019-01-03
Recruiting
Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
NCT06950697Lung Cancer, Venous Thromboembolism, Arterial Thromboembolism, Immune Checkpoint Inhibitors (ICIs)
Beijing Chao Yang Hospital
Observational
2,400
Zhengzhou, Hohhot, Beijing
2019-01-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,240
Heifei, Shanghai, Beijing, Fuzhou Fujian, Guangzhou, Shijiazhuang, Harbin, Zhengzhou
2018-12-27
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,397
Beijing, Chongqing, Xiamen, Guangzhou, Shenzhen, Harbin, Zhengzhou, Wuhan
2018-12-24
Active, closed
Novartis Pharmaceuticals
Phase 3
5,101
Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Nanjing, Suzhou, Changchun
2018-12-07
Active, closed
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
NCT03653507Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
507
Fuzhou, Haikou, Zhengzhou, Changsha, Hengyang, Suzhou, Wuxi, Hangzhou
2018-11-28
Active, closed
AbbVie
Phase 3
265
Beijing, Guangzhou, Zhengzhou, Wuhan, Nanjing, Suzhou, Nanchang, Shenyang
2018-10-22
Active, closed
AbbVie
Phase 2
270
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Baoding, Harbin, Zhengzhou
2018-10-10
Active, closed
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
NCT03589326Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
DrugsPonatinib·Imatinib·Cytarabine·Methotrexate
Takeda
Phase 3
245
Zhengzhou, Suzhou, Changchun, Hangzhou, Tianjin
2018-10-04
Active, closed
3D Medicines (Sichuan) Co., Ltd.
Phase 2
188
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Luoyang, Zhengzhou
2018-08-22
Recruiting
A Study of HQP1351 in Patients With GIST or Other Solid Tumors
NCT03594422Gastrointestinal Stromal Tumor (GIST), Solid Tumor, Adult
Ascentage Pharma Group Inc.
Phase 1
100
Guangzhou, Zhengzhou, Wuhan, Beijing, Shanghai
2018-07-11
Active, closed
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
NCT03504397Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsFolinic acid·Zolbetuximab·Fluorouracil·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
565
Haerbin, Nanjing, Hangzhou, Beijing, Hefei, Xiamen, Zhengzhou
2018-06-21
Active, closed
Exelixis
Phase 3
837
Hefei, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing
2018-06-10
Active, closed
BeiGene
Phase 3
224
Hefei, Beijing, Chongqing, Guangzhou, Shantou, Nanning, Harbin, Zhengzhou
2018-05-14
Active, closed
Daehwa Pharmaceutical Co., Ltd.
Phase 2/3
549
Hefei, Beijing, Guangzhou, Haikou, Harbin, Zhengzhou, Nanjing, Changchun
2017-12-18
Recruiting
China Health Big Data
NCT03699228Osteoporosis, Obesity, Liver Steatoses
Beijing Jishuitan Hospital
Observational
30,000
Wuhu, Beijing, Guiyang, Zhengzhou, Shanghai
2017-12-01
Active, closed
CryoLife, Inc.
Not applicable
202
Beijing, Nanjing, Shanghai, Wuhan, Zhengzhou
2017-11-01
Active, closed
BeiGene
Phase 3
590
Hefei, Beijing, Chongqing, Fuzhou, Quanzhou, Guangzhou, Zhengzhou, Wuhan
2017-10-31
Active, closed
AbbVie
Phase 2
66
Hefei, Beijing, Fuzhou, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha
2017-10-12
Active, closed
Eli Lilly and Company
Phase 3
5,637
Beijing, Fuzhou, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing, Jinan
2017-07-12
Active, closed
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
NCT03173248Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), Leukemia, Myeloid, Acute
DrugsIvosidenib·Azacitidine
Institut de Recherches Internationales Servier
Phase 3
146
Zhengzhou, Chengdu, Beijing, Guangzhou, Hangzhou, Tianjin
2017-06-26
Active, closed
AbbVie
Phase 3
443
Fuzhou, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Nanjing, Changchun, Shanghai
2017-02-02
Recruiting
The First Affiliated Hospital of Zhengzhou University
Observational
3,500
Zhengzhou
2017-01-01
Recruiting
The First Affiliated Hospital of Zhengzhou University
Observational
2,500
Zhengzhou
2017-01-01
Recruiting
The First Affiliated Hospital of Zhengzhou University
Observational
3,000
Zhengzhou
2017-01-01
Recruiting
The First Affiliated Hospital of Zhengzhou University
Observational
3,000
Zhengzhou
2017-01-01
Active, closed
Eli Lilly and Company
Phase 3
463
Bengbu, Beijing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Zhengzhou
2016-12-05
Recruiting
China Registry for Genetic / Metabolic Liver Diseases
NCT03131427Genetic/Metabolic Liver Diseases
Beijing Friendship Hospital
Observational
20,000
Beijing, Guangzhou, Shijiazhuang, Zhengzhou, Shanghai, Chengdu, Tianjin, Ürümqi
2015-06-13
Recruiting
Registry of Multicenter Brain-Heart Comorbidity in China
NCT05961748Ischemic Heart Disease, Cardiac Arrest, Atrial Fibrillation, Heart Failure
Beijing Tiantan Hospital
Observational
100,000
Beijing, Fuzhou, Xiamen, Shenzhen, Harbin, Zhengzhou, Shanghai, Shanxi
2012-01-01
Recruiting
The First Affiliated Hospital of Zhengzhou University
Observational
10,000
Zhengzhou
2010-01-01
Recruiting
The First Affiliated Hospital of Zhengzhou University
Observational
10,000
Zhengzhou
2010-01-01
Recruiting
Azoospermia Patients
NCT03991663Healthy Related
The First Affiliated Hospital of Zhengzhou University
Observational
10,000
Zhengzhou
2010-01-01
Recruiting
Primary Ovarian Insufficient Patients
NCT03989154Healthy Related
The First Affiliated Hospital of Zhengzhou University
Observational
10,000
Zhengzhou
2010-01-01
Rows per page Showing 501–931 of 931
Previous 1 2
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/zhengzhou?page=2

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 931 of those studies with a site in Zhengzhou.

How many clinical trials are recruiting in Zhengzhou?

562 of the 931 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 156 have not yet opened recruitment, 200 are active but closed to new participants, and 13 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.